Mallinckrodt plc will become the second sponsor to virtually present and defend a drug application before a US Food and Drug Administration advisory committee with the 15 July review of terlipressin, a vasopressin analog.
The Cardiovascular and Renal Drugs Advisory Committee will meet via an online teleconferencing platform to consider terlipressin lyophilized powder for...





